Diabetes & Metabolism Journal

Original Article

Basic Research
DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice: Youjin Kim, Si Woo Lee, Hyejin Wang, Ryeong-Hyeon Kim, Hyun Ki Park, Hangkyu Lee, Eun Seok Kang; Diabetes Metab J. 2022;46(2):337-348. Published online January 21, 2022; DOI: https://doi.org/10.4093/dmj.2021.0056

13,482 View
393 Download
22 Web of Science
25 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We investigated the antidiabetic effects of DA-1241, a novel G protein-coupled receptor (GPR) 119 agonist, in vitro and in vivo.
Methods
DA-1241 was administrated to high-fat diet (HFD)-fed C57BL/6J mice for 12 weeks after hyperglycaemia developed. Oral/intraperitoneal glucose tolerance test and insulin tolerance test were performed. Serum insulin and glucagon-like peptide-1 (GLP-1) levels were measured during oral glucose tolerance test. Insulinoma cell line (INS-1E) cells and mouse islets were used to find whether DA-1241 directly stimulate insulin secretion in beta cell. HepG2 cells were used to evaluate the gluconeogenesis and autophagic process. Autophagic flux was evaluated by transfecting microtubule-associated protein 1 light chain 3-fused to green fluorescent protein and monomeric red fluorescent (mRFP-GFP-LC3) expression vector to HepG2 cells.
Results
Although DA-1241 treatment did not affect body weight gain and amount of food intake, fasting blood glucose level decreased along with increase in GLP-1 level. DA-1241 improved only oral glucose tolerance test and showed no effect in intraperitoneal glucose tolerance test. No significant effect was observed in insulin tolerance test. DA-1241 did not increase insulin secretion in INS-1E cell and mouse islets. DA-1241 reduced triglyceride content in the liver thereby improved fatty liver. Additionally, DA-1241 reduced gluconeogenic enzyme expression in HepG2 cells and mouse liver. DA-1241 reduced autophagic flow in HepG2 cells.
Conclusion
These findings suggested that DA-1241 augmented glucose-dependent insulin release via stimulation of GLP-1 secretion, and reduced hepatic gluconeogenesis, which might be associated with autophagic blockage, leading to improved glycaemic control.

Citations

Citations to this article as recorded by

High‐Protein Diet Exacerbates Insulin Resistance via the JNK/IKKβ‐IRS‐1 Pathway
Junjun Li, Jinhua Xu, Jinmiao Tian, Lixia Chen, Lili Zhao, Yongming Yang, Jing Wang, Lei Yan, Yuxin Yang, Yuchen Jiang, Simin Chen, Binxuan Wang, Lulu Wang, Xihua Yang
Endocrinology, Diabetes & Metabolism.2026;[Epub] CrossRef
Human milk fat substitutes improve obesity-related NAFLD by enriching LPC 18:2 to activate hepatic GPR119–AMPK signaling
Yangzheng He, Jing Li, Zhigang Wen, Yong Sun, Liufeng Zheng, Hongyan Li, Zeyuan Deng
Journal of Advanced Research.2026;[Epub] CrossRef
Acute Effects of Cannabinoid Combination Therapies in a Western Diet-Induced Murine Model of Metabolic Liver Disease
Jerome Lian, Mohan Patil, Ricky R. Lareu, Marco Falasca
International Journal of Molecular Sciences.2026; 27(11): 4872. CrossRef
G protein-coupled receptor 119 regulates hepatic lipid homeostasis in zebrafish (Danio rerio)
Changxu Sui, Yuanhui Zhang, Tingting Hao, Fan Chen, Zhiwei Chen, Minglang Chen, Xiuwen Li, Kangsen Mai, Qinghui Ai
Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology.2026; 285: 111251. CrossRef
Discovery of 1,4-Disubstituted Cyclohexene Analogues as Selective GPR119 Agonists for the Treatment of Type 2 Diabetes
Hyunhwa La, Jinwoong Kim, Dae-Hoon Kim, Seong-Heon Kim, Pargat Singh, Gibeom Nam, Kyeongwon Moon, Ikyon Kim, In Su Kim
Journal of Medicinal Chemistry.2025; 68(4): 4619. CrossRef
Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies
Aditi Singh, Sucharita Shadangi, Pulkit Kr. Gupta, Soumendra Rana
Comprehensive Physiology.2025;[Epub] CrossRef
Unraveling the Mystery of Insulin Resistance: From Principle Mechanistic Insights and Consequences to Therapeutic Interventions
Mohammad Muzaffar Mir, Mohammed Jeelani, Muffarah Hamid Alharthi, Syeda Fatima Rizvi, Shahzada Khalid Sohail, Javed Iqbal Wani, Zia Ul Sabah, Waad Fuad BinAfif, Partha Nandi, Abdullah M. Alshahrani, Jaber Alfaifi, Adnan Jehangir, Rashid Mir
International Journal of Molecular Sciences.2025; 26(6): 2770. CrossRef
Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment
Barbara Gieroba, Adrianna Kryska, Anna Sroka-Bartnicka
Biochemistry and Biophysics Reports.2025; 42: 102037. CrossRef
DA-1241, a GPR119 Agonist, Ameliorates Fatty Liver Through the Upregulation of TFEB-Mediated Autophagy
Jin Yoo, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, Myung-Shik Lee, You-Cheol Hwang
Diabetes.2025; 74(7): 1107. CrossRef
Design, synthesis, and antidiabetic activities of 5-methoxypyrimidine derivatives targeting GPR119 and DPP-4
Fukang Yang, Sumei Shi, Shaobing Cheng, Huilan Li, Mai Zhang, Pei Hu, Zunhua Yang, Yuanying Fang
Bioorganic & Medicinal Chemistry.2025; 129: 118318. CrossRef
LC‐MS/MS Assay for Quantification of DA‐1241, a Novel GPR119 Agonist, in Animal and Human Plasma: Application to Preclinical Pharmacokinetic Studies
Seung Jin Kim, Won Seok Bang, Zhengri Li, Mi Hye Kwon, Dae Young Lee, Hee Eun Kang
Journal of Mass Spectrometry.2025;[Epub] CrossRef
G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
Mohan Patil, Ilaria Casari, Leon N. Warne, Marco Falasca
Biomedicine & Pharmacotherapy.2024; 172: 116245. CrossRef
GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates
Deanne H Hryciw, Rhiannon K Patten, Raymond J Rodgers, Joseph Proietto, Dana S Hutchinson, Andrew J McAinch
Expert Opinion on Investigational Drugs.2024; 33(3): 183. CrossRef
Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment
Katarzyna Napiórkowska-Baran, Paweł Treichel, Marta Czarnowska, Magdalena Drozd, Kinga Koperska, Agata Węglarz, Oskar Schmidt, Samira Darwish, Bartłomiej Szymczak, Zbigniew Bartuzi
International Journal of Molecular Sciences.2024; 25(7): 3769. CrossRef
Advances in small-molecule insulin secretagogues for diabetes treatment
Jingqian Su, Jingran Xu, Shan Hu, Hui Ye, Lian Xie, Songying Ouyang
Biomedicine & Pharmacotherapy.2024; 178: 117179. CrossRef
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?
Khaled Al Smadi, Ammar Qureshi, Besher Ashouri, Zeid Kayali
Expert Opinion on Investigational Drugs.2024; 33(9): 877. CrossRef
Chronic metabolic effects of novel gut-oriented small-molecule GPR119 agonists in diet-induced obese mice
Mohan Patil, Dinesh Thapa, Leon N. Warne, Ricky R. Lareu, Elena Dallerba, Jerome Lian, Massimiliano Massi, Rodrigo Carlessi, Marco Falasca
Biomedicine & Pharmacotherapy.2024; 181: 117675. CrossRef
Ganoderma lucidum Spore Powder Alleviates Metabolic-Associated Fatty Liver Disease by Improving Lipid Accumulation and Oxidative Stress via Autophagy
Yuxuan Zhang, Jiali Zhou, Lan Yang, Hang Xiao, Dongbo Liu, Xincong Kang
Antioxidants.2024; 13(12): 1501. CrossRef
Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists
Heecheol Kim, Minjung Kim, Kyujin Oh, Sohee Lee, Sunyoung Lim, Sangdon Lee, Young Hoon Kim, Kwee Hyun Suh, Kyung Hoon Min
European Journal of Medicinal Chemistry.2023; 258: 115584. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
Metabolism.2023; 145: 155612. CrossRef
Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis
Karolien Buyl, Martine Vrints, Ruani Fernando, Terry Desmae, Thomas Van Eeckhoutte, Mia Jans, Jan Van Der Schueren, Joost Boeckmans, Robim M. Rodrigues, Veerle De Boe, Vera Rogiers, Joery De Kock, Filip Beirinckx, Tamara Vanhaecke
European Journal of Pharmacology.2023; 957: 175989. CrossRef
GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling
Seung-Ho Lee, Hansu Park, Eun-Kyoung Yang, Bo Ram Lee, Il-Hoon Jung, Tae-Hyoung Kim, Moon Jung Goo, Yuna Chae, Mi-Kyung Kim
Biomedicine & Pharmacotherapy.2023; 166: 115345. CrossRef
Characteristics of the Latest Therapeutic Agent for Diabetes
Nuri Yun
The Journal of Korean Diabetes.2023; 24(3): 148. CrossRef
DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice
Youjin Kim, Si Woo Lee, Hyejin Wang, Ryeong-Hyeon Kim, Hyun Ki Park, Hangkyu Lee, Eun Seok Kang
Diabetes & Metabolism Journal.2022; 46(2): 337. CrossRef
Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target
Chun-Liang Chen, Yu-Cheng Lin
International Journal of Molecular Sciences.2022; 23(17): 10055. CrossRef

First
Prev
Page of 1
Next
Last

Search